Morad Nasseri1, Seymur Gahramanov1, Joao Prola Netto1, Rongwei Fu1, Leslie L Muldoon1, Csanad Varallyay1, Bronwyn E Hamilton1, Edward A Neuwelt1. 1. Department of Neurology, Oregon Health & Science University, Portland, Oregon (M.N., S.G., J.P.N., L.L.M., C.V., E.A.N.); Department of Public Health and Preventative Medicine, Oregon Health & Science University, Portland, Oregon (R.F.); Department of Emergency Medicine, Oregon Health & Science University, Portland, Oregon (R.F.); Department of Neuroradiology, Oregon Health & Science University, Portland, Oregon (B.E.H.); Department of Neurosurgery, Oregon Health & Science University, Portland, Oregon (E.A.N.); Department of Veterans Affairs Medical Center, Portland, Oregon (E.A.N.); Department of Neurosurgery, Swedish Neuroscience Institute, Seattle, Washington (S.G.); Department of Neurosurgery, Wayne State University, Detroit, Michigan (M.N.).
Abstract
BACKGROUND: Diagnosis of pseudoprogression in patients with glioblastoma multiforme (GBM) is limited by Response Assessment in Neuro-Oncology (RANO) criteria to 3 months after chemoradiotherapy (CRT). Frequency of pseudoprogression occurring beyond this time limit was determined. Survival comparison was made between pseudoprogression and true progression patients as determined by using perfusion magnetic resonance imaging with ferumoxytol (p-MRI-Fe). METHODS: Fifty-six patients with GBM who demonstrated conventional findings concerning for progression of disease post CRT were enrolled in institutional review board-approved MRI protocols. Dynamic susceptibility-weighted contrast-enhanced p-MRI-Fe was used to distinguish true progression from pseudoprogression using relative cerebral blood volume (rCBV) values. rCBV of 1.75 was assigned as the cutoff value. Participants were followed up using RANO criteria, and survival data were analyzed. RESULTS: Twenty-seven participants (48.2%) experienced pseudoprogression. Pseudoprogression occurred later than 3 months post CRT in 8 (29.6%) of these 27 participants (ie, 8 [14.3%] of the 56 patients meeting the inclusion criteria). Overall survival was significantly longer in participants with pseudoprogression (35.2 months) compared with those who never experienced pseudoprogression (14.3 months; P < .001). CONCLUSIONS: Pseudoprogression presented after 3 months post CRT in a considerable portion of patients with GBM, which raises doubts about the value of the 3-month time limit of the RANO criteria. Accurate rCBV measurement (eg, p-MRI-Fe) is suggested when there are radiographical concerns about progression of disease in GBM patients, regardless of any time limit. Pseudoprogression correlates with significantly better survival outcomes.
BACKGROUND: Diagnosis of pseudoprogression in patients with glioblastoma multiforme (GBM) is limited by Response Assessment in Neuro-Oncology (RANO) criteria to 3 months after chemoradiotherapy (CRT). Frequency of pseudoprogression occurring beyond this time limit was determined. Survival comparison was made between pseudoprogression and true progression patients as determined by using perfusion magnetic resonance imaging with ferumoxytol (p-MRI-Fe). METHODS: Fifty-six patients with GBM who demonstrated conventional findings concerning for progression of disease post CRT were enrolled in institutional review board-approved MRI protocols. Dynamic susceptibility-weighted contrast-enhanced p-MRI-Fe was used to distinguish true progression from pseudoprogression using relative cerebral blood volume (rCBV) values. rCBV of 1.75 was assigned as the cutoff value. Participants were followed up using RANO criteria, and survival data were analyzed. RESULTS: Twenty-seven participants (48.2%) experienced pseudoprogression. Pseudoprogression occurred later than 3 months post CRT in 8 (29.6%) of these 27 participants (ie, 8 [14.3%] of the 56 patients meeting the inclusion criteria). Overall survival was significantly longer in participants with pseudoprogression (35.2 months) compared with those who never experienced pseudoprogression (14.3 months; P < .001). CONCLUSIONS: Pseudoprogression presented after 3 months post CRT in a considerable portion of patients with GBM, which raises doubts about the value of the 3-month time limit of the RANO criteria. Accurate rCBV measurement (eg, p-MRI-Fe) is suggested when there are radiographical concerns about progression of disease in GBM patients, regardless of any time limit. Pseudoprogression correlates with significantly better survival outcomes.
Authors: Csanad G Varallyay; Eric Nesbit; Rongwei Fu; Seymur Gahramanov; Brendan Moloney; Eric Earl; Leslie L Muldoon; Xin Li; William D Rooney; Edward A Neuwelt Journal: J Cereb Blood Flow Metab Date: 2013-03-13 Impact factor: 6.200
Authors: E Van Mieghem; A Wozniak; Y Geussens; J Menten; S De Vleeschouwer; F Van Calenbergh; R Sciot; S Van Gool; O E Bechter; P Demaerel; G Wilms; P M Clement Journal: Eur J Neurol Date: 2013-05-17 Impact factor: 6.089
Authors: Seymur Gahramanov; Leslie L Muldoon; Csanad G Varallyay; Xin Li; Dale F Kraemer; Rongwei Fu; Bronwyn E Hamilton; William D Rooney; Edward A Neuwelt Journal: Radiology Date: 2012-11-30 Impact factor: 11.105
Authors: Leland S Hu; Jennifer M Eschbacher; Joseph E Heiserman; Amylou C Dueck; William R Shapiro; Seban Liu; John P Karis; Kris A Smith; Stephen W Coons; Peter Nakaji; Robert F Spetzler; Burt G Feuerstein; Josef Debbins; Leslie C Baxter Journal: Neuro Oncol Date: 2012-05-03 Impact factor: 12.300
Authors: R F Barajas; D Schwartz; H L McConnell; C N Kersch; X Li; B E Hamilton; J Starkey; D R Pettersson; J P Nickerson; J M Pollock; R F Fu; A Horvath; L Szidonya; C G Varallyay; J J Jaboin; A M Raslan; A Dogan; J S Cetas; J Ciporen; S J Han; P Ambady; L L Muldoon; R Woltjer; W D Rooney; E A Neuwelt Journal: AJNR Am J Neuroradiol Date: 2020-06-11 Impact factor: 3.825
Authors: Alissa A Thomas; Julio Arevalo-Perez; Thomas Kaley; John Lyo; Kyung K Peck; Weiji Shi; Zhigang Zhang; Robert J Young Journal: J Neurooncol Date: 2015-08-15 Impact factor: 4.130
Authors: Shannon Puhalla; William Elmquist; David Freyer; Lawrence Kleinberg; Chris Adkins; Paul Lockman; John McGregor; Leslie Muldoon; Gary Nesbit; David Peereboom; Quentin Smith; Sara Walker; Edward Neuwelt Journal: Neuro Oncol Date: 2015-05 Impact factor: 12.300
Authors: Gerda B Toth; Csanad G Varallyay; Andrea Horvath; Mustafa R Bashir; Peter L Choyke; Heike E Daldrup-Link; Edit Dosa; John Paul Finn; Seymur Gahramanov; Mukesh Harisinghani; Iain Macdougall; Alexander Neuwelt; Shreyas S Vasanawala; Prakash Ambady; Ramon Barajas; Justin S Cetas; Jeremy Ciporen; Thomas J DeLoughery; Nancy D Doolittle; Rongwei Fu; John Grinstead; Alexander R Guimaraes; Bronwyn E Hamilton; Xin Li; Heather L McConnell; Leslie L Muldoon; Gary Nesbit; Joao P Netto; David Petterson; William D Rooney; Daniel Schwartz; Laszlo Szidonya; Edward A Neuwelt Journal: Kidney Int Date: 2017-04-20 Impact factor: 10.612
Authors: Runze Yang; Susobhan Sarkar; Daniel J Korchinski; Ying Wu; V Wee Yong; Jeff F Dunn Journal: Neuro Oncol Date: 2017-03-01 Impact factor: 12.300
Authors: Melissa A Prah; Mona M Al-Gizawiy; Wade M Mueller; Elizabeth J Cochran; Raymond G Hoffmann; Jennifer M Connelly; Kathleen M Schmainda Journal: J Neurooncol Date: 2017-09-12 Impact factor: 4.130